Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01HL145435 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
| Columbia University | OTHER |
| University of Alabama at Birmingham | OTHER |
| Stanford University |
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to follow participants who enrolled in the Lung Transplant Outcomes Group. Clinical data, functional assessments, and surveys will be collected to determine long term graft function and functional status of lung transplant recipients.
This project will involve both retrospective and prospective data collection from participants enrolled in the LTOG cohort studies. We will perform long-term Chronic Lung Allograft Dysfunction (CLAD) phenotyping of lung transplant recipients who participated in the LTOG cohort studies utilizing data collected for routine clinical visits. Surviving lung transplant recipients who participated in the LTOG cohort studies will be recruited to enroll in the longitudinal portion of the project. The longitudinal component will include follow-up data collection at 6 month intervals while alive until study termination, study withdrawal, or no longer being seen for follow-up at the participating center. Follow-up data collection will include clinical data collected by study coordinators by reviewing medical records, functional assessment through administration of the Short Physical Performance Battery (SPPB), blood collection and surveys. Data from this project will be linked to data and samples collected during the LTOG cohort or ancillary studies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Chronic Lung Allograft Dysfunction (CLAD) phenotyping | Change in pulmonary function measured by serial pulmonary function tests (PFTs) and data collected at clinical care visits will be used to assess CLAD. | From date of transplant to the development of CLAD, up to 25 years |
| Functional status phenotyping | Change in functional status will be measured by the Short Physical Performance Battery (SPPB). The SPPB is a 3-construct measure that includes gait speed, chair stands, and balance. Each construct is scored from 0 - 4 yielding an aggregate score ranging from 0 - 12. Lower SPPB scores reflect increased frailty. | From date of transplant to until study termination, withdrawal, or no longer being seen for follow-up at the participating center, up to 25 years |
| Well being phenotyping-LT-VLA | Change in well being will be measured by patient reported outcomes including the LT-VLA scale. The LT-VLA scale presents a list of activities and asks respondents to rate their difficulty in performing each one on a 4-point scale. A higher score on the LT-VLA indicates more disability. | From date of transplant to until study termination, withdrawal, or no longer being seen for follow-up at the participating center, up to 25 years |
| Well being phenotyping-LT-QOL | Change in well being will be measured by patient reported outcomes including the Lung Transplant Quality of Life (LT-QOL) survey. The Lung Transplant Quality of Life (LT-QOL) survey will be used to measure disease specific QOL. The LT-QOL utilizes 5 point scales for all items. The general quality of life scale is scored so that higher scores indicate better QOL. | From date of transplant to until study termination, withdrawal, or no longer being seen for follow-up at the participating center, up to 25 years |
Not provided
Not provided
Inclusion criteria
Long-term phenotyping of CLAD
Long-term functional status and well-being
Exclusion Criteria
Long-term phenotyping of CLAD
Long-term functional status and well-being
Not provided
Not provided
Not provided
Lung transplant recipients who have previously enrolled in the LTOG cohort studies at one of the participating centers.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jason Christie, MD | University of Pennsylvania | Principal Investigator |
| Scott Palmer, MD | Duke University | Principal Investigator |
| Jonathan Singer, MD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294 | United States | ||
| University of California San Francisco |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012059 | Rejection, Psychology |
| ID | Term |
|---|---|
| D012919 | Social Behavior |
| D001519 | Behavior |
Not provided
Not provided
| OTHER |
| Johns Hopkins University | OTHER |
| University of Michigan | OTHER |
| University of Pittsburgh | OTHER |
| Duke University | OTHER |
| Indiana University | OTHER |
| University of California, San Francisco | OTHER |
Not provided
Not provided
Not provided
Plasma and buffy coat
| San Francisco |
| California |
| 94143 |
| United States |
| Stanford University | Stanford | California | 94305 | United States |
| Indiana University | Indianapolis | Indiana | 46202 | United States |
| Johns Hopkins University | Baltimore | Maryland | 21224 | United States |
| University of Michigan | Ann Arbor | Michigan | 48109 | United States |
| Columbia University | New York | New York | 10027 | United States |
| Duke University | Durham | North Carolina | 27710 | United States |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | United States |